Keywords

atrial fibrillation, new oral anticoagulants (NOACs), warfarin, anticoagulation

Abstract

Atrial fibrillation (AF) affects millions of Americans and puts them at increased risk for ischemic stroke. It is important for providers to recognize AF and know when it is appropriate to treat patients with anticoagulation. There are several options available for anticoagulation. Warfarin is the most widely used anticoagulant. Other alternatives to warfarin are new oral anticoagulants (NOACs) which are increasingly prescribed in recent years. It is vital providers know the differences between warfarin and NOACs, and what is the most appropriate anticoagulant to use for their patient with AF. The purpose of this paper is to review the clinical presentation of AF and compare the use of warfarin versus NOACs for the prevention of ischemic stroke.